UCLA ALZHEIMERS DISEASE RESEARCH CENTER

加州大学洛杉矶分校阿尔茨海默病研究中心

• 批准号: 8363418
• 负责人: JEFFREY L. CUMMINGS
• 金额: $ 2.01万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2012-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8363418
• 关键词: African American; Alzheimer' s Disease; Alzheimer' s disease model; Amyloid; Amyloid deposition; Antibodies; Apolipoproteins; Award; Basic Science; Behavioral; Brain; Clinical; DNA Library; Data; Databases; Dementia; Diagnosis; Dimensions; Doctor of Philosophy; Education; Frontotemporal Dementia; Funding; Genetic; Genotype; Goals; Grant; Hispanics; Image; Image Analysis; Inflammation; Infusion procedures; Investigation; Lewy Body Disease; Medical center; Modeling; National Center for Research Resources; Olives - dietary; Patients; Pilot Projects; Population; Principal Investigator; Publications; Publishing; Research; Research Infrastructure; Research Personnel; Resources; Role; Scientist; Signal Transduction; Source; Techniques; Tissues; Toxic effect; United States National Institutes of Health; Vascular Dementia; Vascular Diseases; abstracting; clinical research site; computational anatomy; cost; follow-up; image archival system; medical schools; neuropathology; programs

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This application proposes the establishment of an Alzheimer's Disease Research Center (ADRC) at UCLA. The theme of the ADRC is "understanding the mechanisms and optimizing the treatment of Alzheimer's disease". An ADRC would add a basic science dimension to established activities of the current UCLA Alzheimer's Disease Core Center (ADCC), use tissues and antibodies from the ADCC Neuropathology Core, and facilitate an invigorating interchange between clinical scientists and the growing cadre of basic scientists at UCLA. The ADCC has accomplished its original goals and established a flow of well characterized patients that are being followed longitudinally (Clinical Core); accessioned 148 brains into the ADCC brain bank (Neuropathology Core); created an imaging archive with sophisticated image analysis techniques available to investigators (Imaging Subcore of Imaging and Genetics Core); developed mechanisms for routine genotyping and established a DNA bank for genetic investigations (G enetics Subcore of Imaging and Genetics Core); and engaged more than 3600 clinicians in educational programs (Education/Information Transfer Core). The ADCC database contains information on 1261 patients and controls, and in the past year we have achieved an annualized follow-up rate of 90%. In the past 5 years, we have awarded funding for 12 Pilot Projects; these projects have contributed to 10 funded grants and 22 publications. The ADCC has three clinical sites, each serving a different ethnic population: UCLA (primarily majority culture patients), Martin Luther King Medical Center/Drew Medical School (primarily an African-American population), and Olive View Medical Center (an Hispanic population). UCLA investigators using data from the Cores have advanced understanding of frontotemporal dementias, dementia with Lewy bodies, behavioral aspects of AD, the role of vascular disease in AD and vascular dementia, and the role of imaging and genetics in the diagnosis and characterizatio n of AD. ADCC investigators published 375 articles and 338 abstracts on dementia-related topics between 1993 and 1997. Three basic science projects are being proposed: 1) apolipoprotein influences on amyloid deposition (Greg Cole, Ph.D.), 2) amyloid deposition, toxicity, and inflammation in an amyloid infusion model of AD )Sally Frautschy, Ph.D.) and intracellular amyloid signaling (Istvan Mody, Ph.D.). The activities of the Cores will be continued an expanded in the ADRC and the Project Leaders will be integrated into all aspects of the ADRC.

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 这项申请建议在加州大学洛杉矶分校建立阿尔茨海默病研究中心(ADRC)。ADRC的主题是“了解阿尔茨海默病的发病机制和优化治疗方法”。ADRC将在目前加州大学洛杉矶分校阿尔茨海默病核心中心(ADCC)现有活动的基础上增加基础科学方面的内容，使用ADCC神经病理学核心中心的组织和抗体，并促进临床科学家和加州大学洛杉矶分校不断壮大的基础科学家队伍之间的活跃交流。ADCC已经实现了最初的目标，建立了一批特征良好的纵向跟踪患者流(临床核心)；将148个大脑纳入ADCC脑库(神经病理学核心)；创建了研究人员可用的复杂图像分析技术的成像档案(成像和遗传学核心)；开发了常规基因分型机制，并建立了用于遗传学研究的DNA库(G遗传学成像和遗传学核心)；并聘请了3600多名临床医生参与教育项目(教育/信息传输核心)。ADCC数据库包含1261名患者和对照的信息，在过去的一年里，我们实现了90%的年化随访率。在过去5年中，我们为12个试点项目提供了资金；这些项目为10个资助赠款和22个出版物作出了贡献。ADCC有三个诊所，每个诊所服务于不同的种族人群：加州大学洛杉矶分校(主要是多数族裔患者)、马丁·路德·金医学中心/德鲁医学院(主要是非裔美国人)和奥利弗·维尤医疗中心(西班牙裔人口)。加州大学洛杉矶分校的研究人员使用这些核心的数据，对额颞痴呆、路易体痴呆、AD的行为方面、血管疾病在AD和血管性痴呆中的作用，以及成像和遗传学在AD诊断和特征中的作用有了更深入的了解。ADCC调查人员在1993至1997年间发表了375篇关于痴呆症相关主题的文章和338篇摘要。提出了三个基础科学项目：1)载脂蛋白对淀粉样蛋白沉积的影响(Greg Cole，Ph.D.)，2)淀粉样蛋白沉积、毒性和AD淀粉样蛋白注射模型中的炎症)Sally Frautschy，Ph.D.和细胞内淀粉样蛋白信号(Istvan Mody，Ph.D.)。核心的活动将在亚洲发展研究中心继续并扩大，项目领导人将融入亚洲发展研究中心的所有方面。